Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

Cagrilintide

Plain-language summaryIntrigue 75 / 100

Cagrilintide is a long-acting amylin analog from Novo Nordisk, built by attaching a fatty-acid chain to a modified amylin so it binds plasma albumin and circulates for about a week (versus less than an hour for native amylin). It uses the same long-acting trick as semaglutide. The strategic value is that combining cagrilintide with semaglutide hits both the GLP-1 and amylin systems, and phase 2 trials of the combination (CagriSema) showed weight loss exceeding semaglutide alone, approaching tirzepatide territory. Phase 3 trials are ongoing. The amylin axis is a credible second front in obesity treatment alongside the incretins. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

64/100

First long-acting amylin agonist with serious clinical data, best used in combination with GLP-1 agents

Look, cagrilintide has a legitimate claim to being the most interesting amylin compound in the space right now, which isnt saying that much given how thin the long-acting amylin field has been until very recently. Pramlintide has been around since 2005 and requires three injections a day; that practical burden alone kept the amylin receptor largely unexplored as a serious obesity pharmacology target. Cagrilintide’s C18 fatty acid modification for albumin binding solves the half-life problem entirely, extending from under an hour for native amylin to roughly seven days. That’s a real pharmacological advance built on a proven albumin-binding strategy, and its the reason this compound deserves serious attention.

The mechanism is worth taking seriously on its own terms. Amylin acts through the area postrema and nucleus tractus solitarius, slowing gastric emptying and generating satiety signals through brainstem circuits that are largely distinct from where GLP-1 receptor agonists engage. When you combine these, you’re hitting complementary central satiety pathways at different neuroanatomical levels and with different temporal profiles. That’s the rationale behind the CagriSema phase 2 data showing up to 17 percent body weight loss at 32 weeks, approaching the magnitude of bariatric surgery outcomes. The fact that this exceeds what semaglutide produces alone at comparable doses suggests genuine additive pharmacology rather than simple dose escalation of overlapping mechanisms. For an investigator interested in the neurobiology of appetite and energy balance, that complementary signal is the most interesting thing going in metabolic pharmacology right now besides the triple agonists.

What holds the overall score back is honest accounting. Cagrilintide as a standalone is less compelling than in combination. The amylin receptor literature is still thin, basic downstream signaling questions are unresolved, and the REDEFINE phase 3 program will answer questions the phase 2 data deliberately left open. Single developer means external replication of core efficacy claims is limited. We also dont have a clean experimental separation of how much of CagriSema’s effect is driven by cagrilintide specifically versus interaction terms with semaglutide, and that separation is a real and tractable research problem.

Differentiation from pramlintide is enormous on practical grounds. Differentiation from the dual-agonist incretins depends on whether complementary amylin pharmacology adds clinically meaningful efficacy beyond what GIP/GLP-1 dual agonism already captures. That question is unresolved and genuinely worth bench time. For investigators building an obesity pharmacology program, probing central satiety circuitry, or evaluating combination incretin strategies, cagrilintide belongs in the toolkit. For most other research programs, its relevant only at the periphery. Honestly, phase 3 readout will move this score considerably in one direction or the other.

Novelty

60

Mechanism promise

68

In-category differentiation

65

Evidence quality

58

Translational signal

68

Research bench value

60

Rationale Cagrilintide scores on genuinely distinct mechanism and strong phase 2 combination signal, but is held back by single-developer context, phase 3 pending, and the fact that its most compelling data is combinatorial rather than standalone. The amylin receptor space was nearly dormant before this compound, which adds novelty points, but also means the surrounding literature is thin.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Long-acting amylin analog

A long-acting amylin analog with attached fatty acid for albumin binding; under development as an obesity treatment in combination with semaglutide.

Abstract

Cagrilintide (CAS 1415456-37-9; modified amylin analog with C18 fatty acid attached at lysine for albumin binding; molecular weight approximately 4870 Da) is a long-acting amylin receptor agonist developed by Novo Nordisk for obesity. The compound is structurally derived from pramlintide with addition of a C18 fatty acid linker for albumin binding (the same long-acting strategy as semaglutide), extending plasma half-life from less than 1 hour for amylin to approximately 7 days for cagrilintide. Phase 1 and 2 trials in obesity demonstrated dose-dependent weight loss; in combination with semaglutide (the CagriSema combination), phase 2 trials showed up to 17 percent body weight loss at 32 weeks, approaching the magnitude of bariatric surgery. Phase 3 trials (REDEFINE program) are ongoing. Plasma half-life supports once-weekly subcutaneous dosing. Used as the prototype long-acting amylin agonist in metabolic research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-294Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Mazdutide

Plain-language summaryIntrigue 72 / 100

Mazdutide is a long-acting dual GLP-1 and glucagon receptor agonist developed by Eli Lilly and out-licensed to Innovent Biologics for development in China. Mechanistically similar to cotadutide and the natural peptide oxyntomodulin, but with a fatty-acid extension supporting once-weekly rather than daily dosing. Phase 2 trials in Chinese type 2 diabetes and obesity populations showed dose-dependent weight loss and HbA1c reduction comparable to or exceeding semaglutide at higher dose tiers. Phase 3 trials are ongoing in China. It is shaping up to be the first dual GLP-1/glucagon agonist to reach a major market, beating its Western competitors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

55/100

Solid dual GLP-1/glucagon agonist with real Phase 2 human signal, but a crowded class and triple-agonist competition cap its ceiling

Look, mazdutide is a genuinely interesting peptide in a genuinely crowded lane. It’s a dual GLP-1/glucagon receptor agonist — modified glucagon backbone, GLP-1 activity grafted in, C18 fatty acid extension for once-weekly dosing — developed by Lilly and out-licensed to Innovent Biologics for the Chinese market. The mechanism does something single GLP-1 agonists don’t: the glucagon arm drives measurable thermogenesis and energy expenditure on top of the GLP-1-mediated appetite suppression, which is at least theoretically a better handle on weight loss than appetite alone.

Here’s the thing though. The dual GLP-1/glucagon mechanism isn’t new. Oxyntomodulin is the natural endogenous template. Cotadutide (AstraZeneca/Pfizer) ran into this space years ago. Survodutide from Boehringer Ingelheim is also in late development on the same dual axis. So mazdutide isn’t defining its category — its competing for second or third position in a class that retatrutide (triple GIP/GLP-1/glucagon) is already threatening to supersede entirely. On differentiation, the compound’s phase 2 data is encouraging — dose-dependent HbA1c reduction and weight outcomes at higher tiers that track with or slightly exceed semaglutide — but thats not the same as being best-in-class when tirzepatide and retatrutide exist.

We think the evidence base is legitimately respectable for where mazdutide sits developmentally. Phase 2 data are real, multi-site, and the DREAMS Phase 3 program in China is ongoing. There’s a clear human signal for the mechanism, which is more than most peptides in the library can claim. What we dont get is the certainty of full Phase 3 readout or the regulatory history that would push evidence quality into the 70s.

From a research bench standpoint, mazdutide is useful primarily as a reference compound for the long-acting dual GLP-1/glucagon format. Investigators studying the glucagon thermogenesis contribution, the energy expenditure differential versus pure GLP-1, or the pharmacokinetic profile of C18-extended dual agonists have a reason to reach for it. It’s not irreplaceable — survodutide and cotadutide cover overlapping ground — but it’s a credible tool in that niche.

Honestly, the compound’s story is hard to tell without returning to the question of where it sits relative to retatrutide. If triple agonists prove out in Phase 3 with the weight loss magnitude early data suggests, dual GLP-1/glucagon becomes a historical stepping stone rather than a destination. Mazdutide is worth watching, worth understanding, and a solid addition to a research library focused on incretin pharmacology. It’s just not the lead compound in that conversation anymore.

Novelty

58

Mechanism promise

73

In-category differentiation

35

Evidence quality

54

Translational signal

62

Research bench value

48

Rationale Mazdutide scores well on mechanism and translational signal — the glucagon-driven energy expenditure layer on top of GLP-1 appetite suppression is real pharmacology with Phase 2 HbA1c and weight data to back it — but differentiation is the key drag: cotadutide, survodutide, and above all retatrutide make mazdutide a follower in a class it doesn’t define. The compound’s China-centric development trajectory also limits global bench relevance.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GLP-1 / glucagon dual receptor agonist

A long-acting dual GLP-1 and glucagon receptor agonist; under development for obesity and type 2 diabetes.

Abstract

Mazdutide (IBI362, LY3305677; modified peptide with glucagon backbone and GLP-1 modifications; molecular weight approximately 4500 Da) is a dual GLP-1/glucagon receptor agonist developed by Eli Lilly and out-licensed to Innovent Biologics for development in China. The compound is structurally and mechanistically similar to cotadutide and oxyntomodulin, with C18 fatty acid extension for once-weekly dosing. Phase 2 trials in type 2 diabetes and obesity demonstrated dose-dependent HbA1c reduction and weight loss comparable to or exceeding semaglutide at higher dose tiers. Phase 3 trials are ongoing in China (DREAMS program) and US. The dual mechanism produces increased energy expenditure (glucagon effect) on top of the GLP-1 appetite suppression. Used as a reference long-acting dual GLP-1/glucagon agonist.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-296Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cotadutide

Plain-language summaryIntrigue 65 / 100

Cotadutide is a dual GLP-1 and glucagon receptor agonist from AstraZeneca, investigated for type 2 diabetes, fatty liver disease, and obesity. It is a balanced co-agonist (about 5:1 GLP-1 to glucagon). The GLP-1 component does the usual incretin work: insulin release, glucagon suppression, appetite reduction. The glucagon component independently raises energy expenditure and lipolysis, theoretically adding fat-burning on top of appetite suppression. Phase 2 trials showed strong glycemic and weight effects. AstraZeneca de-prioritized it in 2023 in favor of other pipeline assets, leaving its commercial future unclear. The dual-agonist concept lives on in mazdutide and survodutide. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

63/100

Dual GLP-1/glucagon agonist with a genuine NASH thesis and real Phase 2 metabolic signal

Cotadutide sits in an interesting position in the incretin landscape. It’s not tirzepatide, it’s not retatrutide, and it was never meant to be. What it is: a carefully balanced dual GLP-1/glucagon agonist with a specific research thesis around hepatic fat clearance that pure GLP-1 drugs can’t match on mechanism.

The core design is a roughly 30 amino acid peptide with a C16 fatty acid extension, biased approximately 5:1 GLP-1:glucagon at receptor. The GLP-1 side handles what you’d expect: glucose-dependent insulin secretion, glucagon suppression, appetite attenuation. The glucagon component is where it gets interesting. Glucagon receptor activation in the liver directly drives fatty acid oxidation and lipolysis independent of the GLP-1 effects. Thats the NASH thesis: if you can drive hepatic fat clearance through a mechanism that pure GLP-1 agonism doesnt fully access, you get additive benefit at the liver. Phase 2 data (NCT03205761 and related trials from the AstraZeneca program) showed both superior weight loss versus matched-dose GLP-1 monoagonist controls and meaningful hepatic fat reduction on MRI-PDFF, which is the endpoint NASH investigators actually care about.

We think the mechanism promise here is genuine. The dual-target design isn’t just stacking two agonists; the glucagon axis contributes something mechanistically distinct to the hepatic fat story. That makes cotadutide more than a me-too in the incretin space, even with tirzepatide and retatrutide in the picture. The GIP/GLP-1 axis that tirzepatide exploits and the triple agonism retatrutide is chasing are complementary programs, not direct replacements for this specific hepatic mechanism.

What we don’t love: differentiation is real but incomplete. Retatrutide already includes glucagon co-agonism as part of a more ambitious mechanism stack, which raises the question of where cotadutide fits long-term if triple agonists clear Phase 3. The NASH indication might be the answer. Resmetirom (a THR-beta agonist) is now the first approved MASH therapy, but combination approaches pairing a metabolic backbone compound with a thyroid receptor modulator are an obvious next direction, and cotadutide is a better-characterized reference for the GLP-1/glucagon axis than most alternatives in that conversation.

As a research tool, cotadutide earns its place as the reference dual GLP-1/glucagon agonist for metabolic research programs. If you want to specifically dissect what glucagon co-agonism contributes to a GLP-1 backbone in hepatic and metabolic endpoints, this is the probe you reach for. Evidence base is Phase 2 with Phase 3 ongoing, methodology is solid, and the AstraZeneca program has been transparent with the data. Honest score: real signal, useful probe, genuine mechanism differentiation, but not yet at the top tier of this class until Phase 3 reads out.

Novelty

62

Mechanism promise

76

In-category differentiation

55

Evidence quality

57

Translational signal

63

Research bench value

63

Rationale Scores well on mechanism (dual hepatic-targeted design is mechanistically distinct from pure GLP-1 agonism) and translational signal (Phase 2 data shows HbA1c, weight, and hepatic fat reduction vs matched GLP-1 controls), but differentiation is moderated by retatrutide’s triple agonism and the Phase 3 readout is still pending. Placed novel-promising given the NASH-specific research angle and genuine bench utility as the reference GLP-1/glucagon dual agonist probe.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GLP-1 / glucagon dual receptor agonist

A dual GLP-1 and glucagon receptor agonist; investigated for type 2 diabetes, NASH, and obesity.

Abstract

Cotadutide (MEDI0382; CAS 2125247-22-1; modified peptide with glucagon backbone and GLP-1 modifications; approximately 30 amino acid peptide with C16 fatty acid extension; molecular weight approximately 4140 Da) is a dual GLP-1/glucagon receptor agonist developed at AstraZeneca for type 2 diabetes, non-alcoholic steatohepatitis (NASH), and obesity. The compound is a balanced co-agonist (approximately 5:1 GLP-1:glucagon ratio at receptor). The GLP-1 component drives glucose-dependent insulin secretion, glucagon suppression, and appetite reduction; the glucagon component independently increases hepatic fatty acid oxidation, energy expenditure, and lipolysis. Phase 2 trials demonstrated superior weight loss and HbA1c reduction compared to GLP-1 monoagonists at matched dose, with hepatic fat reduction supporting the NASH indication. Plasma half-life supports once-daily subcutaneous dosing; phase 3 development is ongoing. Used as a reference dual GLP-1/glucagon agonist in metabolic research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-295Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Dasatinib

Plain-language summaryIntrigue 80 / 100

Dasatinib (Sprycel) is a multi-target kinase inhibitor approved in 2006 for chronic myeloid leukemia and Philadelphia-chromosome-positive ALL. The longevity world cares about it for a different reason: in 2015, Kirkland and Tchkonia at Mayo Clinic showed that dasatinib combined with quercetin (a natural flavonoid) selectively kills senescent cells, those zombie cells that accumulate with age and pump out inflammatory signals. The combination, dubbed D+Q, became the prototype senolytic regimen and is in human trials for diabetic kidney disease, Alzheimer disease, and idiopathic pulmonary fibrosis. The intermittent dosing (a few days per month) is meant to clear senescent cells without sustained kinase inhibitor exposure. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

60/100

Canonical senolytic tool compound with real clinical pipeline but evidence still maturing

Look, dasatinib is a case where the original compound and the interesting research are almost two different things. As a BCR-ABL/Src kinase inhibitor for CML, it’s a well-understood oncology tool that’s been on the market since 2006. That part of the story is mature. What we’re interested in here is the senolytic application, which is effectively a different compound in terms of what investigators are actually doing with it.

The Kirkland and Tchkonia group at Mayo Clinic is the origin point for the D+Q framing. The 2015 paper in Aging Cell showed that dasatinib preferentially kills senescent fat cell progenitors while leaving healthy cells largely intact, and quercetin covers the epithelial senescent cell population that dasatinib misses. The mechanism isn’t just “it’s cytotoxic”; it’s targeting the pro-survival networks senescent cells depend on: ephrin receptors, BCR-ABL-related kinase activity in mesenchymal lineages, PI3K/AKT signaling. Selective enough to be useful, broad enough to clear the target population. Thats a real biological lever, and it makes the D+Q framing more than a convenience stack.

Clinical translation is moving. There’s a 2019 pilot in idiopathic pulmonary fibrosis (Kirkland, published in EBioMedicine) showing improved physical function measures in a small N. Trials in diabetic kidney disease have shown some early eGFR-related signals. The Alzheimer’s indication is under active investigation across multiple sites. What we dont have yet is a clean phase 3 confirmation; the trials are phase 1/2, mostly single-site, and effect sizes in the early data are modest. The IPF result looks real but hasn’t been replicated at scale.

Where dasatinib earns its keep in a research library is bench utility. If you’re running a senolytic program, this is your reference compound for the mesenchymal compartment. You can’t do credible senolytic biology without it as a comparator. The combination with quercetin is the canonical positive control in the field. That’s indispensable tool value even before you factor in the clinical translation story.

What we like: the mechanism is genuinely interesting, the clinical pipeline is real, and this compound occupies a position no other small molecule currently fills in aging biology. What we don’t like: the evidence base for the senolytic indication is still early, the oncology-derived dosing (even the intermittent 3-days-per-month approach) carries a meaningful adverse effect profile that complicates healthy-aging research design, and the human signal needs considerably more work before anyone should treat this as a resolved story. Compelling for investigators in the senolytic space; not yet a priority for those working adjacent to it.

Novelty

52

Mechanism promise

65

In-category differentiation

68

Evidence quality

52

Translational signal

55

Research bench value

72

Rationale Dasatinib scores primarily on differentiation and bench utility as the reference mesenchymal senolytic in the D+Q combination; novelty is tempered by its 2006 approval and now-decade-old senolytic repurposing, and the clinical evidence base remains phase 1/2 with modest effect sizes and limited replication.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tyrosine kinase inhibitor / senolytic

A multi-target tyrosine kinase inhibitor approved for chronic myeloid leukemia; repurposed in senolytic combination therapy with quercetin (D+Q).

Abstract

Dasatinib (BMS-354825; CAS 302962-49-8; molecular formula C22H26ClN7O2S; molecular weight 488.01) is a multi-target tyrosine kinase inhibitor developed at Bristol-Myers Squibb and approved by the FDA in 2006 under the trade name Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive ALL. The senolytic application emerged from work by Kirkland and Tchkonia at Mayo Clinic (2015 onward) demonstrating that the combination of dasatinib (targeting senescent cells of mesenchymal origin) and quercetin (targeting senescent cells of epithelial origin) selectively eliminates senescent cells while sparing healthy cells. The D+Q regimen has been advanced into multiple clinical trials in idiopathic pulmonary fibrosis, diabetic kidney disease, Alzheimer disease, and other age-related conditions, with intermittent dosing (e.g., 100 mg daily for 3 days monthly) hypothesized to clear accumulated senescent cells without continuous chemotherapy exposure. Plasma half-life is approximately 5 hours; metabolism is via CYP3A4. Used as the canonical senolytic small molecule with clinical translation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-297Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Retatrutide

Plain-language summaryIntrigue 91 / 100

Retatrutide is a triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously. The glucagon component adds a fat-burning effect on top of the appetite suppression and glucose control of GLP-1/GIP. Phase 3 trials are ongoing for obesity. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel frontier

82/100

Triple GIP/GLP-1/glucagon agonist with extraordinary Phase 2 weight-loss signal, currently the frontier of metabolic peptide research

Look, the GLP-1 era already redrew metabolic pharmacology, and tirzepatide added GIP to that picture. Retatrutide adds the third piece: glucagon receptor agonism. That’s not incremental. Stacking glucagon on top of dual incretin signaling gives you a compound that hits appetite through GLP-1, potentiates insulin dynamics through GIP, and drives hepatic energy expenditure and lipolytic output through glucagon. Three distinct pathways, one weekly injection. The pharmacological rationale is genuinely elegant.

The Jastreboff et al. Phase 2 trial, published in NEJM in 2023, showed 24.2 percent body weight reduction at 48 weeks in the highest-dose arm. That’s not a modest signal. Tirzepatide in SURMOUNT-1 topped out around 20.9 percent at 72 weeks. Retatrutide got further, faster. The dose-response curve is clean, the dropout rates manageable, and the effect on MASH markers adds another dimension the earlier incretins didn’t have. We’re not reading between the lines here, the Phase 2 data is unusually strong.

Mechanism-wise, the glucagon component deserves more attention than it usually gets in lay discussion. Glucagon receptor agonism in isolation would raise glucose, which sounds counterproductive. But in the context of GLP-1 and GIP coadministration, the hepatic energy expenditure and fat oxidation effects dominate while the hyperglycemic risk is substantially blunted. Its a balance thats been validated in rodent models and appears to hold in humans. Whether the hepatic effects specifically drive the MASH signal is still being worked out in ongoing arms of the trial.

What we like here is the research density. Retatrutide is useful as a probe for dissecting the incretin-glucagon axis in ways tirzepatide simply can’t address. You can ask questions about what glucagon receptor activation specifically contributes to metabolic outcomes by comparing the two compounds head-to-head in preclinical models. That’s real bench utility, not just clinical noise. The three-receptor design also opens questions about receptor crosstalk and downstream signaling that single or dual agonists leave on the table.

What we don’t like is the access picture. This is an investigational compound still in trials, not approved, not commercially available outside of study enrollment. Sourcing for preclinical work is achievable but not straightforward, and quality verification matters more here than with mature peptides. The long-term cardiovascular profile and the glucagon safety signal across diverse populations still need the Phase 3 readout to fully settle. But the Phase 2 results are the strongest weight-loss signal any injectable metabolic peptide has produced in a well-designed trial, and the mechanism has serious depth. For anyone working on incretin biology, metabolic regulation, or MASH models, retatrutide is the compound to watch right now.

Novelty

88

Mechanism promise

90

In-category differentiation

88

Evidence quality

68

Translational signal

80

Research bench value

68

Rationale Scores high across novelty, mechanism, and differentiation because adding glucagon receptor agonism to dual incretin pharmacology is genuinely new territory with strong pharmacological rationale, and Phase 2 human data showing 24.2% weight loss at 48 weeks is the strongest single-agent metabolic signal on record. Evidence score is moderated because Phase 3 is ongoing and regulatory status remains unconfirmed.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GIP/GLP-1/glucagon triple receptor agonist

An Eli Lilly investigational triple receptor agonist of GIP, GLP-1, and glucagon receptors with Phase 3 trials in obesity producing 24% weight loss at 48 weeks.

Abstract

Retatrutide (LY3437943) is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors developed by Eli Lilly and currently in Phase 3 trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). The compound builds on the GIP/GLP-1 dual agonist tirzepatide platform by adding glucagon receptor agonism, which contributes additional weight loss through hepatic energy expenditure increases and lipolytic effects. Phase 2 obesity trial results published in 2023 showed approximately 24.2 percent weight loss at 48 weeks at the highest dose, exceeding the magnitude observed with tirzepatide. The compound is not yet FDA approved; Phase 3 program is ongoing. Pharmacokinetics: weekly subcutaneous administration; half-life supports once-weekly dosing. The triple agonist class represents the current frontier of metabolic peptide development.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-084Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
FOXO4-DRI Peptide

Our opinion on this compoundNovel, promising

59/100

Elegant senolytic probe targeting the FOXO4-p53 axis, but single-lab preclinical with no human data

Look, the de Keizer 2017 Cell paper genuinely changed how the field thought about senescent cell survival. The core insight is elegant: senescent cells dont die the way they should because FOXO4 physically sequesters nuclear p53, keeping it away from its apoptotic signaling role. FOXO4-DRI is a retroinverso peptide, all D-amino acids with a reversed sequence, that competitively disrupts that interaction. Release p53, and senescent cells kill themselves. Healthy cells, which dont rely on the FOXO4-p53 interaction for survival, are largely spared. That selectivity profile is what separates this from blunter instruments like navitoclax or ABT-263, which hit BCL-2 family members broadly and carry meaningful toxicity.

The retroinverso design is worth understanding. D-amino acids make the peptide protease-resistant in a way that L-amino acid counterparts simply arent; the reversed sequence preserves the structural mimicry of the FOXO4 target region while delivering a pharmacokinetically more tractable molecule. A penetratin sequence handles cell entry. As research tools go, this is carefully engineered, not a peptide fragment someone threw at a model.

What we like here is the mechanism specificity. Most senolytics in the current literature are repurposed oncology drugs (navitoclax) or phenolic compounds with broad polypharmacology (dasatinib plus quercetin). A peptide operating directly at a protein-protein interface defined by senescent cell biology is a much cleaner probe. If you want to ask what happens when you remove senescent cells without the noise of BCL-2 inhibition or kinase off-targets, FOXO4-DRI is one of the few tools that lets you do it.

The problems are real, though. The Hubrecht group dominates the primary literature; external replication of the full rejuvenation story is limited, and the 2017 mouse data showing improved fur density, kidney function recovery, and enhanced physical performance has been cited extensively but not reproduced cleanly outside the originating lab at the same scale. There are no human clinical trials. Synthesis of D-retroinverso peptides at research grade is possible but not commoditized, so sourcing adds friction.

Honestly, the bench value is what keeps this genuinely interesting. For investigators studying the SASP, comparing senolytic modalities in aging tissue models, or probing p53 biology in the context of cellular senescence, this is a nearly irreplaceable tool. Theres nothing else that hits the FOXO4-p53 axis the same way. The score reflects that the preclinical case is real and the probe is unique, but the evidence base is thin and the translational distance is long.

Novelty

65

Mechanism promise

78

In-category differentiation

68

Evidence quality

38

Translational signal

25

Research bench value

72

Rationale The de Keizer Cell 2017 mechanism is genuinely novel and the selectivity profile distinguishes this from blunter senolytics, pushing mechanism and differentiation scores meaningfully above field average. Evidence and translational scores are sharply constrained by Hubrecht-group concentration in the primary literature and a complete absence of human trials, landing the overall at 59.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Cell-penetrating peptide senolytic

A retroinverso D-amino acid peptide that disrupts the FOXO4-p53 interaction in senescent cells, selectively triggering apoptosis.

Abstract

FOXO4-DRI (FOXO4-D-retroinverso peptide; sequence ltlrkepaseiaqsileayqqgs in D-amino acids; molecular weight approximately 2700 Da) is a designed cell-penetrating peptide senolytic developed by de Keizer and colleagues at the Hubrecht Institute. The compound is a retroinverso peptide derived from the FOXO4 sequence that competitively disrupts the FOXO4-p53 interaction; in senescent cells, FOXO4 sequesters nuclear p53 and prevents apoptosis. The DRI peptide releases p53, which translocates to mitochondria and triggers selective apoptosis in senescent cells while sparing healthy cells (which do not depend on the FOXO4-p53 interaction for survival). Mouse studies (Cell 2017) demonstrated dramatic rejuvenation of fur density, kidney function, and physical performance in aged mice. The retroinverso D-amino acid construction confers protease resistance; cell penetration is supported by an attached penetratin sequence. No human clinical trials at this writing. The compound is a research tool for academic senolytic biology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-300Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tirzepatide

Plain-language summaryIntrigue 93 / 100

Tirzepatide, sold as Mounjaro and Zepbound, is the first dual GLP-1 and GIP receptor agonist. By activating both incretin receptors, it produces more weight loss than semaglutide in head-to-head trials. Approved by the FDA in 2022. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel frontier

80/100

Dual incretins done right: the FDA-approved benchmark that defines what GIP/GLP-1 co-agonism can achieve

Look, tirzepatide isn’t just another incretin. The whole story starts at the receptor pharmacology: GIP and GLP-1 agonism together produce a genuinely additive effect that neither receptor achieves alone. GIP engagement modulates adipose tissue metabolism and potentiates insulin secretion in a glucose-dependent fashion; GLP-1 handles central satiety signaling, gastric emptying delay, and glucagon suppression. Running both pathways simultaneously turns out to be more than the sum of its parts, and the SURMOUNT program is the evidence base that confirmed it at scale.

SURMOUNT-1, published in the New England Journal of Medicine in 2022, showed average weight loss of 20.9% at the 15 mg weekly dose in adults with obesity over 72 weeks, with N above 2500. These arent modest numbers from a single lab. SURMOUNT-2, -3, and -4 extended the findings to T2DM populations, confirmed durability after withdrawal, and locked in the dose-response relationship. Multiple RCTs, multiple populations, consistent signal. The evidence quality here is genuinely high for a peptide compound.

What we find most interesting from a research standpoint is what the GIP component actually contributes. GLP-1 monotherapy was already well-validated before tirzepatide arrived. In a real sense, tirzepatide is the controlled experiment for what layering GIP receptor agonism adds on top of established GLP-1 biology. The GIP receptor’s role in adipose tissue, its interactions with adiponectin signaling, and the downstream effects on fat mass independent of energy intake are not fully characterized, and tirzepatide is one of the few available probes for studying that biology at clinically meaningful concentrations.

We dont think it’s breaking news anymore, though. Tirzepatide is FDA-approved, widely prescribed, and the research program is maturing fast. Novelty has a shelf life, and this compound is burning through it. Retatrutide is already in phase 2 with a triple agonist profile adding glucagon receptor activity, which makes tirzepatide look like a stepping stone in a rapidly evolving pharmacology story. Bench investigators focused purely on incretin frontier biology will want to be watching that space closely.

For investigators working on metabolic pharmacology, incretin receptor biology, adipose tissue signaling, or GLP-related satiety circuitry, tirzepatide remains one of the most useful tools available. The evidence base is unusually clean. The mechanism is well-defined. And the gap it opened between dual and single GLP-1 agonism is exactly the kind of differentiated signal that gives a research program somewhere real to go. The score reflects a compound that genuinely moved the field, even as the field is already starting to move past it.

Novelty

72

Mechanism promise

85

In-category differentiation

80

Evidence quality

87

Translational signal

88

Research bench value

68

Rationale Tirzepatide scores high on mechanism promise and evidence quality because the SURMOUNT trial program is unusually clean and large for a peptide this young, and the dual-receptor pharmacology is genuinely differentiated from GLP-1 monotherapy. Novelty is real but moderating now that it’s an approved, widely-prescribed agent; retatrutide’s emergence makes tirzepatide look increasingly like the floor of what’s possible in this class rather than the ceiling.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GIP/GLP-1 dual receptor agonist

A dual GIP and GLP-1 receptor agonist FDA-approved as Mounjaro (T2DM, 2022) and Zepbound (obesity, 2023), producing greater weight loss than GLP-1-only agents.

Abstract

Tirzepatide (Mounjaro, Zepbound; CAS 2023788-19-2; molecular weight 4813.54) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor co-agonist developed by Eli Lilly and approved by the FDA for type 2 diabetes (2022) and chronic weight management (2023). The compound is a 39-amino-acid synthetic peptide based on the GIP scaffold with modifications at positions enabling GLP-1 receptor agonism alongside GIP receptor activity. Mechanism is dual GIP/GLP-1 receptor agonism producing complementary effects: GIP engagement adds to GLP-1’s glucose-dependent insulin secretion and contributes to weight regulation through fat metabolism modulation; GLP-1 contributes the central satiety, gastric emptying, and glucagon suppression effects. The combination produces substantially greater weight loss than GLP-1 monotherapy: SURMOUNT trials showed 15 to 22 percent weight loss over 72 weeks at 5 to 15 mg weekly doses. Approved doses titrate to 5, 10, or 15 mg per week subcutaneous.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-083Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vinpocetine

Plain-language summaryIntrigue 50 / 100

Vinpocetine (Cavinton) is a synthetic alkaloid derived from vincamine in the lesser periwinkle plant, developed at Gedeon Richter in Hungary in the 1960s. Approved across Europe for cerebrovascular insufficiency and used as a nootropic in the US (sold as a supplement). It works through several mechanisms at once: cerebral vasodilation, weak phosphodiesterase 1 inhibition, neuronal sodium channel block, and modest antioxidant activity, with the combined effect of improving blood flow to the brain. Clinical evidence in cognitive impairment and stroke recovery is mixed and dominated by older Eastern European trials with weak methodology. The FDA flagged it in 2019 over concerns about miscarriage in pregnant users. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

32/100

A 1960s cerebrovascular workhorse with weak PDE1 inhibition that has been surpassed by more selective modern tools

Vinpocetine is one of those compounds that was genuinely interesting in 1975 and has been coasting on that reputation ever since. Developed at Gedeon Richter in Hungary as a synthetic derivative of vincamine, it got approval across Eastern Europe under the Cavinton trade name and built up a moderately sized clinical literature, mostly through the 1980s and 1990s. That history is real. The problem is that the research has barely moved since.

The mechanism is pluripotent in the way that usually signals we don’t really know what’s driving the effect. PDE1 inhibition is the most cited angle, and it’s not a bad one; PDE1B and PDE1C have legitimate neurological relevance, and the cyclic nucleotide signaling cascade downstream is genuinely interesting biology. But vinpocetine’s PDE1 affinity is weak relative to selective inhibitors that came later. The cerebrovascular vasodilation story is real but not mechanistically novel. The sodium channel block exists but is modest. What you end up with is a compound that does several things modestly well rather than one thing exceptionally.

Differentiation is where vinpocetine struggles most against modern alternatives. If you’re interested in PDE1 specifically, ITI-214 (now lenrispodun) is a selective, high-affinity PDE1 inhibitor with clean human pharmacology data and a phase 2 trial in heart failure. If you want cerebrovascular effects, the field has largely moved to better-characterized agents. Vinpocetine competes with neither, and its FDA story is awkward: the agency has questioned whether it legally qualifies as a dietary supplement given its pharmaceutical development history, which creates a real sourcing ambiguity for US-based research programs.

The evidence base is an honest moderate score. There’s a multi-decade literature, some small RCTs in European populations, and a Cochrane review that found evidence insufficient to support use in dementia. Not nothing. But a lot of the primary literature comes from Eastern European groups with methodological standards that dont hold up well against modern expectations, and independent replication from Western labs is sparse. The translational signal exists, it’s just not compelling by current standards.

We think vinpocetine still has marginal utility as a rough PDE1 inhibitor tool in preclinical CNS work, particularly when selectivity isn’t the priority and broad cerebrovascular modulation is the goal. Thats a narrow use case. For investigators seriously studying PDE1 biology, ITI-214 is the right probe. For cerebrovascular research, the compound landscape looks very different in 2025 than it did when Cavinton was approved. Vinpocetine is a historical artifact that still holds a slot in the library, but serious bench scientists should know what they’re not getting when they reach for it.

Novelty

20

Mechanism promise

32

In-category differentiation

28

Evidence quality

45

Translational signal

40

Research bench value

35

Rationale Developed in the 1960s with a multi-decade Eastern European clinical literature, vinpocetine’s pluripotent-but-weak mechanism and poor differentiation against selective modern PDE1 inhibitors keep novelty and differentiation scores low; evidence quality is moderate given the Cochrane-reviewed RCT base, but independent Western replication is sparse and effect sizes are modest throughout.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic vincamine derivative / cerebrovascular agent

A synthetic alkaloid derivative of vincamine from Vinca minor; a cerebrovascular agent and PDE1 inhibitor used as a nootropic.

Abstract

Vinpocetine ((3-alpha,16-alpha)-eburnamenine-14-carboxylic acid ethyl ester; CAS 42971-09-5; molecular formula C22H26N2O2; molecular weight 350.46) is a synthetic alkaloid derivative of vincamine from Vinca minor (lesser periwinkle), developed at Gedeon Richter (Hungary) in the 1960s and approved in many European countries as Cavinton for cerebrovascular insufficiency. Mechanism is multifactorial: cerebral vasodilation through smooth muscle relaxation, weak phosphodiesterase 1 (PDE1) inhibition, sodium channel block in neurons, and modest antioxidant activity. The combined effect produces improved cerebral blood flow and reduced ischemic neuronal injury in animal stroke models. Plasma half-life is approximately 1 to 2 hours; metabolism is hepatic via CYP2C9 and CYP3A4. Approved indications in Europe include cerebrovascular disorders, age-related cognitive decline, and tinnitus. In the US, the compound is sold as a dietary supplement with FDA reservations about that designation given its drug-like history. Used as a cerebrovascular nootropic and PDE1 inhibitor in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-305Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vincamine

Plain-language summaryIntrigue 35 / 100

Vincamine is the natural indole alkaloid extracted from Vinca minor (lesser periwinkle), the parent compound that vinpocetine was derived from. It shares the cerebral-vasodilation and modest phosphodiesterase-inhibition profile with vinpocetine but is shorter-acting and less lipophilic. Approved in France (as Pervincamine) and Italy for cerebrovascular insufficiency and mild dementia. Largely supplanted by vinpocetine in markets where both are available, owing to the latter’s better pharmacokinetics. Of mainly historical interest as the natural starting point for the eburnane vasodilator class. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

28/100

Parent compound of vinpocetine; superseded by its own derivative with limited independent research value

Look, vincamine occupies a specific and somewhat awkward position in the research landscape: it’s the parent compound of vinpocetine, which means its most important historical contribution was getting chemically modified into something better. That’s not a great story for a research target in 2026.

The mechanism isn’t the issue per se. Cerebral vasodilation via smooth muscle relaxation, mild PDE inhibition, some antioxidant activity in mitochondrial fractions. These are real biological effects, but they’re not novel and have been well-characterized for decades. France approved it as Pervincamine; Italy uses it for cerebrovascular insufficiency and age-related cognitive decline. That approval history gives it more clinical anchoring than most peptides on research shelves, which is something. But the underlying mechanism class has had a rough few decades in terms of clinical translation for dementia-adjacent indications, and vincamine specifically isn’t a bright spot in that story.

The differentiation problem is hard to argue around. Vinpocetine is more lipophilic, crosses the blood-brain barrier more efficiently, has a longer half-life (roughly 2-3 hours vs vincamine’s approximately 1 hour), and carries substantially more published literature from independent groups. If you’re asking a bench-level question about the eburnane alkaloid scaffold, vincamine is the historical reference; it’s not the compound you’d choose to answer that question with today. The derivative wins almost every comparison you’d care about.

Thats not to say vincamine is worthless. For labs doing comparative scaffold chemistry, looking at the eburnane core versus its semisynthetic variants, vincamine is the natural starting material and the reference point. There’s legitimate synthetic and pharmacokinetics work where having the parent compound matters. We also think the European approved-drug status means the safety and tolerability file is cleaner than for most research compounds in this space, and the multi-decade literature gives you methodological precedent to work from.

What we don’t like is how little of that literature is modern, replicated by independent groups, or aimed at anything beyond the fairly ill-defined category of cerebrovascular insufficiency, an indication the field has largely moved away from. Most of the published clinical work predates 2000 and is of variable methodological quality by current standards.

Honestly, if you’re building out an eburnane scaffold comparative program, vincamine belongs in the collection as a reference compound. For any other purpose, the resource allocation case is weak. Vinpocetine does what vincamine does, only better, which is a hard position to argue your way out of.

Novelty

22

Mechanism promise

27

In-category differentiation

18

Evidence quality

38

Translational signal

40

Research bench value

32

Rationale Vincamine scores poorly on novelty and differentiation because it’s a decades-old European-approved cerebrovascular agent whose semisynthetic derivative outperforms it on nearly every pharmacokinetic and research-utility dimension; evidence quality is modest given the largely pre-modern clinical literature, and the mechanism is unremarkable cerebrovascular dilation plus weak PDE inhibition.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Periwinkle alkaloid / cerebrovascular agent

An indole alkaloid from Vinca minor; the parent compound of vinpocetine, used as a cerebrovascular agent in Europe.

Abstract

Vincamine ((3-alpha,14-beta,16-alpha)-14,15-dihydro-14-hydroxyeburnamenine-14-carboxylic acid methyl ester; CAS 1617-90-9; molecular formula C21H26N2O3; molecular weight 354.45) is an indole alkaloid isolated from Vinca minor (lesser periwinkle). The compound is the natural precursor of vinpocetine, sharing the eburnane scaffold but with reduced lipophilicity and shorter duration of action. Mechanism: cerebral vasodilation, modest PDE inhibition, antioxidant activity. Approved in several European countries (notably France as Pervincamine and Italy) for cerebrovascular insufficiency, mild dementia, and age-related cognitive decline. Plasma half-life is approximately 1 hour; oral bioavailability is moderate. Used as a cerebrovascular agent in academic research and as the historical reference compound for the eburnane class.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-306Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Hydergine (Ergoloid Mesylates)

Our opinion on this compoundEstablished workhorse

28/100

Historical ergoloid mixture with diffuse mechanism, inconsistent modern evidence, and no competitive angle against current alternatives

Look, Hydergine has a genuinely interesting pedigree. Albert Hofmann developed it at Sandoz in the 1940s, and for several decades it was among the most-prescribed drugs on the planet for age-related cognitive decline. That history matters as context. But historical ubiquity and research merit in 2026 are very different things, and Hydergine scores low here for reasons that get clearer the closer you look.

The pharmacology is honestly a mess. It’s a fixed mixture of four dihydrogenated ergoloid alkaloids in a 3:3:2:1 ratio, and the proposed mechanisms read like a catalog of everything researchers thought might matter in 1965: alpha-adrenergic antagonism, weak dopaminergic and serotonergic modulation, some effect on neuronal energy metabolism, and antioxidant activity the abstract itself describes as weak. None of that is factually wrong. But none of it is a crisp pharmacological hypothesis either. You’re not probing a defined receptor system with a selective tool; you’re applying a multi-component ergoloid mixture to a preparation and watching a diffuse readout. The mechanism being incompletely characterized after 70-plus years of use is not a sign of deep mystery worth investigating. It’s a sign the signal was never clean enough to resolve.

The evidence picture is even harder to defend. Cochrane-style systematic reviews of Hydergine for dementia and cognitive decline have repeatedly returned inconsistent benefit, with effect sizes that are modest at best and unreliable across trials. This isnt a compound that lost a fair fight to superior competitors. It’s a compound whose initial approvals predated rigorous RCT design, and when methodology improved, the signal did not hold up. Cholinesterase inhibitors and memantine have replaced it in clinical practice for well-documented reasons, and no serious dementia or cognitive aging program is anchored on ergoloid alkaloids today.

Differentiation is essentially negative. On every dimension that matters for a 2026 research program, Hydergine is outclassed: cleaner mechanism compounds exist for each of its proposed targets individually, and the multi-target case is weaker than it looks because the components were not rationally combined for synergy.

What we think: the only realistic bench use-case is as an ergoloid reference standard for comparative alkaloid pharmacology or for historical context in nootropic mechanism reviews. That keeps bench value from hitting the floor entirely, but it doesnt rescue the compound as an active research target. The frontier has moved well past it.

Novelty

20

Mechanism promise

28

In-category differentiation

20

Evidence quality

42

Translational signal

30

Research bench value

38

Rationale Developed in the 1940s and once globally ubiquitous, Hydergine’s multifactorial mechanism remains incompletely characterized and modern systematic reviews return inconsistent cognitive benefit; it has been supplanted clinically by cholinesterase inhibitors and retains only narrow ergoloid reference value for bench work.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Ergoloid mixture (dihydroergocornine, dihydroergocristine, dihydroergocryptine)

A mixture of dihydrogenated ergoloid alkaloids; used historically for cognitive decline and as a senescence-associated nootropic.

Abstract

Hydergine (codergocrine mesylate; CAS 8067-24-1; mixture of dihydroergocornine, dihydroergocristine, and dihydroergocryptine alpha and beta isomers in 3:3:2:1 ratio; molecular weight approximately 660 to 700 Da) is a mixture of dihydrogenated ergoloid alkaloids developed at Sandoz (now Novartis) by Albert Hofmann in the 1940s. The compound was approved for senescence and senile mental status in many countries from the 1950s onward; it was once among the most prescribed drugs globally. Mechanism is multifactorial and incompletely characterized: alpha-adrenergic antagonism, dopaminergic and serotonergic effects, modulation of neuronal energy metabolism, and weak antioxidant activity. Modern systematic reviews have produced inconsistent evidence of cognitive benefit; the compound is largely supplanted in clinical practice by cholinesterase inhibitors and memantine for dementia. Plasma half-life is approximately 5 hours. Used as a historical nootropic and ergoloid reference compound.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-307Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 59 60 61 62 63 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.